Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxychloroquine for Endothelial Dysfunction in Antiphospholipid Syndrome
NCT02595346Phase 2Terminated
- Sponsor
- Rouen University Hospital
- Start
- May 2016
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in antiphospholipid syndrome (APS) comparing Hydroxychloroquine + Standard Treatment with Placebo + Standard Treatment (2 arms). Primary endpoint: Flow Mediated Dilatation of brachial artery at 6 months. Started May 2016; status: terminated.
02
Drugs
hydroxychloroquine
03
Conditions
antiphospholipid syndrome (APS)
Beyond the preview
Go deeper on NCT02595346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02595346.